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Abstract
Introduction: The Microbicides Development Programme evaluated the safety and effectiveness of 0.5% and 2% PRO2000/
5 microbicide gels in reducing the risk of vaginally acquired HIV. In February 2008 the Independent Data Monitoring
Committee recommended that evaluation of 2% PRO2000/5 gel be discontinued due to futility. The Africa Centre site
systematically collected participant responses to this discontinuation.
Methods: Clinic and field staff completed field reports using ethnographic participant observation techniques. In-depth-
interviews and focus group discussions were conducted with participants discontinued from 2% gel. A total of 72 field
reports, 12 in-depth-interviews and 3 focus groups with 250 women were completed for this analysis. Retention of
discontinued participants was also analysed. Qualitative data was analysed using NVivo 2 and quantitative data using STATA
10.0.
Results: Participants responded initially with fear that discontinuation was due to harm, followed by acceptance after
effective messaging, and finally with disappointment. Participants reported that their initial fear was exacerbated by being
contacted and advised to visit the clinic for information about the closure. Operational changes were subsequently made to
the contact procedures. By incorporating feedback from participants, messages were continuously revised to ensure that
information was comprehensible and misconceptions were addressed quickly thereby enabling participants to accept the
discontinuation. Participants were disappointed that 2% PRO2000/5 was being excluded as a HIV prevention option, but
also that they would no longer have access to gel that improved their sexual relationships with their partners and assisted
condom negotiations. In total 238 women were discontinued from gel and 185 (78%) went on to complete their scheduled
follow-up period.
Discussion: The use of qualitative social science techniques allowed the site team to amend operational procedures and
messaging throughout the discontinuation period. This proved instrumental in ensuring that the discontinuation was
successfully completed in a manner that was both understandable and acceptable to participants.
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Introduction
Clinical trials
Clinical trial sponsors, investigators and participants generally
plan for a clinical trial to continue until scheduled completion.
However, trials may be prematurely discontinued for a number of
reasons. As part of the clinical trial governance and monitoring
process, trial data is systematically reviewed for safety and progress
towards primary endpoints by an Independent Data Monitoring
Committee (IDMC). The IDMC has the mandate to recommend
discontinuation of the clinical trial, or part thereof, as it deems fit
on the following basis: 1) if the new treatment demonstrates
significant effectiveness, 2) if the new treatment demonstrates
safety concerns or harm to the participants; or 3) if it is clear that
efficacy will not be demonstrated (futility) [1–3].
Microbicide clinical trials
Microbicides are experimental products which may reduce the
risk of HIV infection for women during sexual intercourse. To
date seven microbicides have entered clinical trials evaluating
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product effectiveness [4] and three trials evaluating two products
have been prematurely halted. Family Health International trials
of SAVVY microbicide were stopped in Ghana in 2005 due to
declining HIV incidence and in Nigeria in 2006 on the basis of
product futility [5,6]. The following year a CONRAD trial
evaluating Cellulose Sulphate microbicide was discontinued on the
basis of potential harm [7]. FHI subsequently halted its trial of
Cellulose Sulphate as a precautionary measure without any
indication of harm [8]. The initial closure of the CONRAD
Cellulose Sulphate trial on the basis of a higher number of HIV
infections in women using the product received extensive media
coverage in KwaZulu-Natal [9] although the final trial results
showing that the product did not cause harm but was futile,
received minimal media coverage [10].
Microbicides Development Programme
The Microbicides Development Programme (MDP) was
established to develop safe, effective, acceptable and affordable
microbicides (http://www.mdp.mrc.ac.uk/). MDP is a partner-
ship of 16 African and European research institutions. The UK
Medical Research Council (MRC) sponsored the MDP301
international, multi-centre, randomised, double-blind, placebo-
controlled, phase III clinical trial that aimed to evaluate the safety
and effectiveness of 0.5% PRO2000/5 and 2% PRO2000/5
microbicide gels in reducing the risk of vaginally-acquired HIV
infection. The design of the overall trial and the integrated social
science component, as well as the trial results have been published
elsewhere [11–13]. The MDP301 trial was conducted at six
clinical trial centres in South Africa, Tanzania, Uganda and
Zambia. The first site commenced enrolment in October 2005. At
enrolment women were randomly assigned to receive 0.5%
PRO2000/5, 2% PRO2000/5 or a placebo gel. The trial was
double-blinded, so neither trial staff nor participants knew to
which gel group participants were allocated. Women enrolled in
the trial were instructed to insert 2 ml of gel vaginally up to one
hour prior to sex from a pre-filled applicator. Participants received
monthly HIV prevention counselling which included support in
negotiating condom use. They were required to return to the
clinics every four weeks for a total of 52 weeks (104 weeks at the
Uganda site). At the end of their follow-up period all unused gel
was collected.
On the 8th February 2008, the IDMC for the MDP301 protocol
met for the sixth time and reviewed data collected on 7,735
women available by 15th January across all six sites. The IDMC
recommended that the evaluation of 0.5% PRO2000/5 in
comparison to the placebo gel continue. However, they recom-
mended that evaluation of 2% PRO2000/5 gel should be
discontinued as there was ‘no more than a small chance of it
showing protection against HIV infection’ [14]. Following the
IDMC recommendation, the MDP Trial Steering Committee
(TSC) met on 11th February 2008 to review the IDMC
recommendations. After careful consideration of the operational,
scientific and ethical issues involved, the IDMC recommendations
to stop evaluation of 2% gel and continue evaluating 0.5% gel
were accepted. Participants were to be discontinued from 2% gel
use as soon as practically possible, they would not be randomised
back into the trial in order to maintain validity of the
randomisation schedule and there were no clinical or ethical
benefits of providing placebo gel to women without it being used
as a comparator for an investigational product.
At the time of the discontinuation, the investigators remained
blinded and were not provided with the data on which the IDMC
made their decision. However, the final trial results demonstrated
that the conditional power for significant benefit from the 0.5%
PRO 2000 gel was sufficient to warrant trial continuation [13].
Africa Centre for Health and Population Studies MDP site
The Africa Centre for Health and Population Studies was one of
six MDP301 clinical trial sites (www.africacentre.ac.za). The
Centre is located in a predominantly rural part of the
Umkhanyakude District of KwaZulu-Natal, South Africa [15].
The Africa Centre joined the MDP network in 2003 but had a well
established institutional community advisory board (CAB) and
long-standing relationships with a broad range of stakeholders
from its inception in 1998. The standard of care package offered to
MDP301 trial participants and their partners was extensively
negotiated with the CAB and other relevant stakeholders, as well
as being revised with trial participants after enrolment commenced
[16,17]. As part of these negotiations, it had been agreed that
before the end of follow-up, trial participants would be informed
about the range of vaginal lubricants available locally, but that
alternative lubricants would not be distributed by the research
team. This decision was based on a number of factors; 1) there
would not be long term clinical follow up after the trial in case of
adverse reactions to lubricants, 2) there was emerging evidence
that over-use of one of the locally available lubricants could disrupt
the vaginal mucosa, and 3) that it could be extremely difficult to
prevent assumptions in the community that over-the-counter
vaginal lubricants had anti-HIV properties. However, at the end
of follow-up each participant had a close-out session which
included a full explanation of trial timelines, result scenarios, plans
for unblinding participants and disseminating results, as well as
plans for post-trial access in the eventuality that the product had
been found safe and effective.
The Microbicide Study Coordinating Committee (MSCC)
served as the management committee for the MDP301 protocol
at the Africa Centre. The MSCC included the trial investigators as
well as coordinators responsible for the clinical, counselling, social
science, data, recruitment, retention, community liaison, labora-
tory and pharmacy components of the trial. The MSCC met on
12th February to discuss the IDMC recommendation and
established procedural guidelines for the discontinuation of trial
participants from the 2% gel arm. Discontinuation was planned to
commence on the 14th February 2008 across all sites in line with
the public release of the discontinuation. The top priorities of the
discontinuation plan at the Africa Centre were: 1) to disseminate
the information quickly and comprehensively to trial participants,
community members and stakeholders; and 2) to discontinue
women from 2% PRO2000/5 gel.
The MSCC developed a script to explain the key messages
(available on request). The script was reviewed during a series of
workshops conducted with staff, participants and community
members. Participants were mainly drawn from the participant
advisory group which was a fluid group of former and current
participants who were invited to attend meetings on various topics
through an established participant at each of the three clinics.
Community members were mainly drawn from the institutional
CAB which included community elected representatives who were
briefed on all aspects of research conducted at the Africa Centre
but were not MDP trial participants. The workshops provided a
platform to ensure that the messages utilized appropriate language
and were comprehensible. The script was presented at meetings
and community events, as well as via local press and radio shows.
Audio recordings were made of the script and played in the clinics.
Underpinning the information dissemination process was a
monitoring strategy designed to collect participant and community
responses to the discontinuation of the 2% gel. The purpose of the
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monitoring exercise was to ensure that information dissemination
procedures were working effectively, disseminated information was
accurately comprehended, and any adverse responses to the
discontinuation were detected and addressed immediately. As a
result of the monitoring strategy, the script and audio recordings
were regularly reviewed and revised to incorporate additional
questions from participants and community members and to
address local misconceptions that were reported to the MSCC,
who met daily during this period.
The MSCC also established a daily reporting mechanism for
the clinic teams to report the number of trial participants who had
been given the information and the number of women
discontinued from 2% gel. MRC supplied a list of trial numbers
that had been allocated to the 2% gel arm of the trial. By the 14th
February 2008, 1,056 women had been enrolled in the trial at the
Africa Centre, with 353 randomised to the 2% gel arm. Of those
on 2% gel, 238 were still within the 52 week follow up period at
the time of discontinuation. All participants on 2% gel were
contacted by telephone where possible or visited at home. At the
time of gel discontinuation, participants underwent pregnancy
testing, HIV counselling and testing and a genital examination
which included the collection of samples to test for sexually
transmitted infections (STIs). Women who were discontinued from
gel use were invited to remain in the study attending only the
quarterly clinical visits instead of also attending the monthly gel
accountability visits. However, women discontinued from 2% gel
were not tracked if they did not return for a quarterly visit after
they had been discontinued as they no longer required clinical
monitoring. This paper presents the responses of participants at
the Africa Centre to the discontinuation of 2% PRO2000/5 gel.
Methods
The clinical trial protocol included approval for ethnographic
participant observations within the trial. When the 2% gel was
discontinued the MSCCmembers developed monitoring systems to
evaluate responses to the discontinuation using these ethnographic
techniques. This included the development of a field report that all
MDP clinic and field staff members were required to complete on a
daily basis. All clinic and field staff regularly presented information
about HIV and theMDP study in the community and therefore had
undergone training in the completion of field reports to capture
community questions and feedback. The reports systematically
documented anonymous information that trial staff were either told
or overheard at the clinics or in the community. These field reports
summarised the participants’ responses to the discontinuation, their
level of comprehension of disseminated information and questions
posed by them. A total of 72 field reports were submitted over 16
days from the 14th to 29th February 2008 documenting views of 216
trial participants regardless which arm of the study they were
randomised to. The field reporting stopped at the end of the month
as the majority of women on 2% gel had been discontinued and
data saturation had been reached. The field reports were
transcribed in English.
The trial protocols social science component included in-depth
interviews (IDI) and focus group discussions (FGDs) with trial
participants. Participants in the IDIs and FGDs provided written
informed consent. Twelve IDIs and 3 FGDs were conducted with
women discontinued from the 2% gel arm. Women in the IDIs
were aged between 19 and 64 years and were discontinued from
gel use between 14th February and 27th March. The FGDs
involved 22 discontinued women aged between 19 and 57 years.
The IDIs and FGDs were conducted in isiZulu and were recorded,
they were transcribed in isiZulu and translated into English.
All of the transcripts of field reports, IDIs and FGDs, were
imported into the qualitative data analysis software NVivo 2 (QSR
International Pty Ltd. Version 2, 2002) and coded according to a
matrix of themes that had been predefined for all community liaison
data collection. The coding themes were developed on the basis of
findings from formative research conducted during earlier feasibility
and pilot studies. The broad coding was based on who had provided
the data (women screened, women enrolled, male partners, women
or men from the community, members of formal community groups,
or community advisory board members) and the topic of discussion
(about the research institution, personal benefit or loss due to
participation, MDP study policies, clinical procedures, or gel). The
clinic attendance of women discontinued from the 2% PRO2000/5
gel at quarterly visits was also monitored and reasons for withdrawals
were documented. This information was recorded on trial case record
forms which were double entered using an Access application with a
SQL Server. The quantitative data was analysed using STATA 10.0
(Stata Corporation, College Station, Texas, USA). At the Africa
Centre the MDP301 clinical trial was approved by the South African
Medicines Control Council (N2/19/8/2) and the University of
KwaZulu-Natal Biomedical Research Ethics Committee (T111/05).
These bodies also reviewed the revised protocol and information
sheets at the time of the discontinuation. Pseudonyms are used in this
paper to maintain participants’ anonymity.
Results
The qualitative analysis highlighted four key topics; 1)
participants responses to the procedures used during discontinu-
ation, 2) participants interpretation of the discontinuation
messages; 3) participants responses to the discontinuation; and 4)
participants responses regarding informing their partners. We also
present quantitative data on how many women decided to remain
in follow-up to the end of the scheduled period after being
discontinued from 2% PRO2000/5 gel.
Participant responses to discontinuation procedures
Initially participants randomised to the 2% gel arm were
contacted by phone if a current phone number was available or
during home visits if a phone number was unobtainable. They
were informed that there was new information about the trial and
asked to visit the clinic as soon as possible instead of waiting for
their next scheduled visit. This was driven by a number of factors;
firstly the nurses and counsellors were considered the most
appropriate staff members to explain the information comprehen-
sively and could take time to address all questions; secondly there
was a concern that by providing only partial information at the
initial contact, participants may not visit the clinics for more
information or may not return with the unused gel applicators;
and thirdly the tracking team consisted of only 4 staff members
and therefore the workload of contacting all participants was
already arduous. However, within the first few days, feedback from
participants indicated that the resulting suspense created signifi-
cant apprehension among them. Participants immediately as-
sumed that the gel must have caused harm. For instance:
‘I thought that it (gel) had some danger because he (study team member)
called twice. I said is there anything that has happened and he said yes
and I asked is it so bad and he said I shouldn’t panic, but I was so
scared.’ Samke, 46 year old, IDI.
The MSCC changed the procedure on the third day of
dissemination. Fieldworkers contacting participants were then
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provided with an abridged script to explain basic information
about the discontinuation, before advising the participant to visit
the clinic for further details. In order to allay fears of harm, the key
discontinuation message was headlined in the script. The majority
of participants responded positively to this procedure as they said
that learning about the discontinuation directly from the study
team was preferable to hearing the news in the community or
media.
Less than half of the telephone numbers provided by
participants were operational and therefore the majority were
visited at home. Some participants reported that even though they
had previously agreed to be visited at home they were
apprehensive when they were visited by the staff vehicle, especially
if they had not disclosed trial participation to family members or
neighbours. The HIV and non-HIV related research work of the
Africa Centre had been continuously explained in community
settings over the previous 10 years. Despite this, and a continuous
presence of Africa Centre vehicles, remnants of a rumour
remained that associated visits by Africa Centre vehicles with a
HIV-positive person being in the household. In an attempt to
mitigate this stigma, study participants were encouraged to
consider these issues before enrolment and to prescribe in
considerable detail the best modes of contact and ‘reasons’ for
contact when a staff member met a family member, work
colleague or neighbour. Some participants requested that research
staff park at a discrete distance and walk instead of drive up to
their houses if home visits were necessary. However, the majority
of women did not define specifications, and for a minority this
appeared to be because they did not expect to require a home visit.
Although some participants would have preferred to have been
contacted by phone, participants were only contacted at home if
the phone number provided by participants was no longer in use.
A solution to the dilemma of wanting to hear the information from
the study team as soon as possible but not wanting to be contacted
at home when an active phone number was not available was
never resolved. However, the MSCC did subsequently increase
procedures that monitored if clinic staff checked contact details
with participants at every monthly visit. The team also suggested
that in subsequent trials it could be helpful to insist on an initial
visit away from the clinic prior to enrolment to ensure that the trial
participant and staff member developed and tested acceptable
modes of contact.
Participants’ interpretation of the discontinuation
messages
The site team recognised that there were specific challenges to
explaining why the higher concentration gel (2%) was being
discontinued and the lower concentration gel (0.5%) was
continuing to be evaluated. The field reports documented how
participants explained this among themselves. One participant
who was a traditional healer explained that in traditional medicine
the aim is to use the weakest concentration possible. She explained
to other participants that she was not at all surprised at the
discontinuation of the higher concentration PRO2000/5 and the
continued evaluation of the lower concentration. One group of
participants likened the discontinuation of 2% gel and continu-
ation of 0.5% gel to having two cups of hot water, both with one
teaspoon of sugar: but, one cup with one teabag and the other cup
with four teabags. The group explained the better cup of tea would
be the one brewed with a single teabag (0.5% gel), not the one with
four teabags (2% gel).
Despite these examples, many participants said that they had
placed more hope on the higher concentration PRO2000/5 gel
and some participants said they had lost hope in the 0.5% gel as a
result of the 2% discontinuation. Field reports observed that
participants indicated that:
‘…they would now pray four times harder for 0.5% gel to work
(against HIV) as it is four times weaker than the 2% gel…’
Nozipho, participant in 40’s, field report.
‘They have doubts for the 0.5% PRO2000/5 gel… They said ‘‘we
are holding our breaths’’ as there is now less hope that the 0.5% will
work.’ Smisiwe, participant in 40’s, field report.
The field reports also identified three misconceptions which
only emerged in a handful of situations but could have spread if
not attended to; 1) the first was that if the IDMC had been able to
see that 2% PRO2000/5 was not likely to prevent HIV infection,
by recommending that 0.5% gel continue the IDMC must have
seen that 0.5% gel was effective against HIV; 2) the second was
that because the 2% gel was stopped due to futility and not
because of harm, there was evidence that 2% PRO2000/5 was
safe and this was also used as an indicator that 0.5% PRO2000/5
must be safe; 3) the third was that the whole trial had been un-
blinded as participants questioned how the site staff, who they
knew were blind to gel allocation, could identify women on 2%
gel. Whilst these interpretations demonstrate a complex under-
standing of the scientific issues, they lead to incorrect assumptions
that the 0.5% gel is effective, safe and unblinded. Messages were
quickly revised or developed to update the script to avoid the
spread of these misconceptions. As a result, these reports dissipated
within the first week of the discontinuation process.
Participant responses to the discontinuation
Overall most participants were calmly accepting of the
discontinuation and the reasons for it. Most of the participants
acknowledged that they were told at the beginning of the trial that
the microbicide gels were being tested and it was not known if they
were effective against HIV, as the following quote demonstrates:
‘It was explained to me that it (gel) was still being tested and if it
doesn’t work it will end like this and you will stop. You cannot continue
with something that doesn’t work…’ Bonisiwe, 33 year old, FGD.
However, despite understanding that PRO2000/5 was an
investigational product, many participants had hoped that the gel
would prove effective against HIV and hence protect them. Thus,
when the discontinuation was announced most women were
deeply disappointed as expressed by the following participants:
‘We had hope because this gel was something of a high note and we
hoped that it (gel) might work and thereafter we could get it from the
chemist. I had that hope.’ Cebile, 46 year old, IDI.
‘…they (study clinic staff) explained to us…that it was not known
whether this thing (gel) will protect us against diseases (HIV). But
because it was tested on me as a person I put my trust in this thing….
but now if it is found that it didn’t help me, hawu (exclamation of
sadness)!’ Thembi, 33 year old, FGD.
Some participants said that their initial response to the news
that the 2% gel arm had been discontinued was fear, with the
immediate conclusion that the gel had been found to be harmful.
Many linked this response to the initial reports of the Cellulose
Sulphate microbicide trial being closed due to safety concern,
which had been heavily publicised in the community. One
participant said in an IDI:
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‘We entered (the clinic room) with another lady and they (clinic staff)
explained…we looked at each other and thought that the gel might be
really harmful. I was just thinking for myself. Everyone was thinking
that but we didn’t ask each other…I told myself that it (gel) is harmful,
in other words I’m infected. Then the blood was taken and there is
nothing that is left with me (I’m HIV negative).’ Lindiwe, 52 year
old, IDI.
With consistent explanations from the study team, participants’
fears were gradually allayed. However, some participants
expressed concern that community members may assume that
the gel had been discontinued due to increased risk of HIV
infection, as had been the initial report of the Cellulose Sulphate
trial. Participants reported that they promoted their participation
in the trial as a sign of their negative HIV status to friends and
neighbours. They feared that by stopping gel use they may be
assumed to have sero-converted as explained in the following
quote:
‘I think the community will look at us badly because even if you explain
that we have stopped this gel because the gel doesn’t work, not because it
is harmful…the community will tell itself that the gel has been stopped
because we are infected.’ Sizakele, 23 year old, IDI.
Nonetheless, overall there was a general sense of relief among
participants that the discontinuation was due to futility rather than
harm.
Relating information to male partners
Only a few male partners of trial participants visited the clinics
for information about the discontinuation. This meant that the
burden of responsibility to explain the discontinuation rested with
the participants. Most women on 2% gel reported that they did
not tell their partners about the discontinuation until after they
had completed the discontinuation visit. In this way they said they
felt more confident that they could explain the discontinuation.
They also used the HIV test result and the pelvic examination as
‘proof’ that the 2% gel was being discontinued for futility rather
than harm. Participants had clearly discussed their results of the
HIV tests and pelvic examinations between them and used their
collective experience as additional evidence. One participant
explained:
‘I explained to him (partner) that the gel was tested and found not to
prevent HIV as it was expected and he said it is okay if it (gel) hasn’t
done any harm to us. I said that there is nothing (no harm) because we
(participants) were examined and nothing was found.’ Tholakele, 49
year old, FGD.
As has been the experience with most investigational microbi-
cide gels [18–26], most of the participants in the IDIs and FGDs
said the gel had increased their sexual pleasure and improved their
relationships. Some said that their partners were now less likely to
be unfaithful as a result of them using the gel. Therefore, when
discontinuation of the 2% gel arm was announced the concern
about the impact that this would have on relationships and sexual
experiences was dominant. This concern was evident in these
reports:
‘The lady (study field staff) said I was invited to the clinic. I asked
what have I done and she said nothing…take all your gels and bring
them to the clinic. I thought they (clinic staff) were going to add some
gels because they gave me a lot and I (often) returned all of them empty.
The lady said I will not return home with the gels and I said can we
please hide some, but she said no.’ Beauty, 51 year old, FGD.
‘The participant said gel helped her in her relationship since her partner
used to cheat on her (before). She was worried about what she is going to
use now if she has to return all her gel back. She returned home to collect
all her gels and brought them back to the clinic. She was so angry you
could see that on her face.’ Khetiwe, 52 year old, field report.
Many participants reported an increase in condom use since
joining the study and using gel. Many said the positive impact the
gel had on their sexual pleasure made condom use more tolerable
to both them and their partners. The discontinuation raised
concerns that they would no longer be able to negotiate condom
use with their partners:
‘I collected condoms from here in the (study) clinic. I explained to him
that I use this gel not because it would protect us against disease…they
(investigators) do not have proof that the gel protects. (He) agreed and
said that he would use condoms. Before that he did not use condoms.’
Lungeleni, 38 year old, IDI.
‘Gel made my partner behave well and he respected me by wearing
condoms.’ Lindiwe, 52 year old, IDI.
There had always been a lingering apprehension among
participants that once they completed their scheduled follow up
period in the trial that their relationships and their ability to
negotiate condom use would be impacted. During the 2%
discontinuation women most recently enrolled voiced this concern
most loudly. This could have been because women at a later stage
in their follow up period had already started to come to terms with
having to stop using gel at the end of the study.
The majority of participants on 2% gel had disclosed gel use to
the male partners (57% of 325 women who attended their week 4
visit). Participants felt that dealing with the discontinuation was
more complicated for trial participants who had not disclosed gel
use to their partners. They felt that the partners were likely to
notice a reduction in sexual pleasure when the women stopped
using the gel and that the women would find it difficult to explain
the change. A study fieldworker entered the following in her
monitoring report after a conversation with a participant:
‘Her partner had asked her what she is using that makes her ‘‘nice’’ in
bed and because she had not disclosed gel use she answered that she does
not know. Now (that she will no longer be using gel) she was concerned
that her partner will feel the difference and accuse her of cheating and
she might even need to disclose to him that she had been using gel and
she doesn’t know how he is going to take that explanation.’
Nonhlanhla, 20 year old, field report.
Because of all these concerns some participants discontinued
from 2% gel asked to be randomised into the remaining two arms
of the trial, so that they could continue accessing the gel. Other
participants asked to be given the placebo gel. The study team
were under constant pressure to explain why both cases were not
possible, for scientific and ethical reasons.
Due to these concerns participants in the FGDs believed that
most women discontinued from the 2% gel would not return their
unused gel. However, due to consistent and effective messaging,
over 99% of unused 2% gel applicators were returned by
participants who were discontinued from gel use.
Discontinuation of 2% PRO2000
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Attendance after discontinuation
For the purpose of these analyses, ongoing attendance at the
study clinics after gel discontinuation was used as a proxy measure
of acceptance that the information provided was accurate and that
the gel had not caused harm. This is based on the hypotheses that
if women had lost trust or faith in the study they were likely to
decide to no longer attend the study clinics.
Of the 238 participants randomised to the 2% gel arm and still
within the follow up period by February 2008, 209 (88%) were
located and discontinued within 3 weeks of February 14th. An
additional 15 participants were discontinued over a period of 4 to
20 weeks after 14th February. The remaining 14 women had
defaulted on their follow up visits prior to the discontinuation and
were never located.
Before February 2008, 101 (88%) of the 115 women in the 2%
PRO2000/5 gel arm had completed the scheduled trial follow-up,
7 had defaulted and 7 had withdrawn from the trial. Of the 238
women discontinued from the 2% PRO2000/5 gel arm, 185
(78%) completed the scheduled follow-up period, 14 had defaulted
prior to the discontinuation and were never located (as mentioned
above), 2 women died of unrelated conditions before completion,
34 defaulted after the discontinuation visit, and 3 withdrew from
the trial. In fact, 20 participants had only had one follow-up visit
by the time of discontinuation, yet 12 of these completed their
remaining eleven months of follow-up. This high level of follow-up
was attained without any tracking procedures for women
discontinued from 2% gel.
Although the field reports did not exclude women randomised
to 0.5% or placebo gel, this paper focuses on accounts from
women who were discontinued from 2% gel. All enrolled women
(regardless of gel group) were asked to provide written consent to
continue in the trial after the discontinuation had been explained.
Overall women in the other trial arms were relieved that
evaluation of 0.5% gel was continuing, no-one withdraw from
the 0.5% and placebo groups as a result of the discontinuation,
and trial retention and gel adherence was not affected in anyway.
Discussion
This paper set out to systematically review responses of
participants to the discontinuation of the 2% PRO2000/5 gel
arm of the MDP301 clinical trial at the Africa Centre in February
2008. A range of qualitative methods were used which included
field reports, IDIs and FGDs, in order to monitor consistency
between solicited and unsolicited information. The qualitative data
indicated that the participants were generally accepting of the
discontinuation. Quantitative retention data was then used, as a
proxy measure, to monitor consistency between verbal accounts of
acceptance and ‘active’ demonstration of acceptance in terms of
remaining engaged with the study. The fact that 78% of women
discontinued from gel use completed their scheduled follow-up
visits supports the level of acceptance observed in the qualitative
data.
The MDP301 protocol included a substantial social science
component and the application of these qualitative techniques
during the discontinuation period was critical in informing
operational procedures. Feedback from participants within the
first 2 days of the discontinuation resulted in the MSCC changing
the initial contact procedures by the tracking team. This feedback
also facilitated the iterative review of messages and allowed the
team to address misconceptions at their formative stage before
they spread and became entrenched. Initial reports also identified
that participants were concerned about the potential reaction that
their communities may have to the news given the previous media
coverage of the Cellulose Sulphate trial being initially stopped due
to a risk of increased harm. This highlighted the need to hasten
and intensify community level messaging and to prioritise areas
that were known to have significant concentrations of participants.
The utilisation of feedback mechanisms to inform operational
procedure had always been a core component of the trial protocol
and proved invaluable during this unexpected event.
The qualitative data indicated that participants comprehended
the information explaining why the 2% gel arm had been
discontinued. The educational components of the trial and the
regularity with which the key trial messages had been repeated
throughout the trial evidently enabled participants to understand
the discontinuation. For example participants framed the news
within the context of understanding the investigational nature of
the gels and the double-blind trial design. In addition, the
comprehensibility of the discontinuation messages was enhanced
by engaging a broad spectrum of staff as well as participants and
community members in the development of the messages. The
messages were continuously improved through the daily iterative
review process. This ensured that the messages drew on real life
scenarios that had local meaning in isiZulu. For example the
explanation that ‘‘one teabag is better than four’’ was incorporated
to explain that a stronger concentration is not necessarily better
than a weaker concentration at achieving a desired outcome. This
assisted in explaining why 2% PRO2000/5 was being excluded as
a HIV prevention option, but there was still a chance that 0.5%
PRO2000/5 may prove effective as a HIV prevention option. The
ability of the trial team to develop messages in this manner was
supported by the fact that the sponsors provided key messages for
site staff but devolved the responsibility of developing local
messages for participants and community members to the site
investigators. This devolution of responsibility had been estab-
lished across the network from the beginning of the trial as the
sponsors acknowledged the differences between the clinical trial
sites in the network and the different needs of their local
populations.
The utilisation of the qualitative methods also allowed the study
team to quickly gauge the extent to which messages were
misinterpreted or extrapolated to other parts of the trial. For
example, participants interpreted the fact that 2% gel was being
discontinued due to futility to mean that it was safe. They also
extrapolated this to mean that 0.5% PRO2000/5 must also be
safe. These reports highlighted that the messages did not include
the scientific evidence based principle in which there was no
evidence 2% was harmful yet there was not evidence it was safe. It
was crucial for the team to explain this evidence based principle
not only to women discontinued from the 2% gel but to all
participants so as they did not think that the 0.5% gel was ‘safe’
thereby undermining the key message that the trial was evaluating
both effectiveness and safety.
Many participants reported that their initial response to the
news was one of fear and apprehension at the risk of harm. The
fact that participants used their own health status as confirmation
that the gel was discontinued due to futility not harm did not prove
problematic as there were no sero-conversions or genital
abnormalities diagnosed at the discontinuation visits. However, if
there had have been, this link would have been very problematic.
This association stemmed from two issues; firstly the closure of the
Cellulose Sulphate trial the previous year, and; secondly a lack of
knowledge regarding all the circumstances under which a trial, or
part thereof, may be prematurely discontinued. The participant
information sheet only explained that participation in the study
could be stopped prematurely ‘by authorities responsible for
running the trial’. The role of the IDMC was not comprehensively
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explained to all MDP participants until the Cellulose Sulphate
study was closed. However, the fact that a trial, or part thereof,
could also be discontinued due to effectiveness or futility was never
fully explained prior to the 2% discontinuation. This lack of prior
knowledge unduly caused anxiety for participants at the time of
the discontinuation. Whilst it is important for participants to
understand all aspects of the trial before consenting to participate,
there is always a risk of information overload which can result in
the key messages being confused or forgotten. The trial team
consequently decided to introduce comprehensive explanations
about the role of the IDMC and the circumstances under which a
trial may be discontinued to subsequent enrolees as modular
components in the ongoing information sessions that are delivered
throughout the course of the trial.
Overall participants were accepting of the news, but were
disappointed. Whilst participants clearly understood the investi-
gational nature of the trial gels, their dire need for additional HIV
prevention options meant that they ‘hoped’ that the gel would
prove to be a HIV prevention option that they could use in the
future. However, what was also obvious from the reports was that
the disappointment went beyond merely being disappointed that
2% PRO2000/5 was being excluded as a potential HIV
prevention option. For most participants, gel use had resulted in
improvements in their relationships and sexual experiences. Gel
use had also assisted some women in negotiating the use of
condoms with their partners. Consequently, losing the ability to
use gel had much broader impacts on participants’ lives. Basically,
participants perceived discontinuation as a threat to the present
favourable status of their relationships, regardless of the scientific
justification that investigators provided for the decision to
discontinue.
As previously stated, the retention data served as a proxy
measure for ‘active’ demonstration of acceptance of the discon-
tinuation. However, as the qualitative data was collected within
the first few months of discontinuation, it was not possible to
ascertain from this analysis why so many women continued to
attend their three-monthly follow-up visits after their discontinu-
ation from gel. One option is that they wanted to continue to
access the high standard of care offered by the research clinics.
Whilst HIV counselling and testing is widely available in the
community, pelvic examinations and STI tests are not routinely
conducted. A second option may be that given their reports of
using their HIV tests and pelvic examinations as a way to ‘confirm’
that the gel had not ‘harmed’ them, they used the quarterly visits
to continue to check their health status. The site was only able to
facilitate this continued follow-up of participants because only one
arm of the trial was discontinued but the rest of the trial continued
to its scheduled completion 18 months later. If participants did use
the continued follow-up visits as confirmation that the gel had not
caused harm, it raises the question of how participants respond to
trials that close in their entirety prematurely in terms of their own
perception of risk.
Conclusion
The implementation of the monitoring systems proved instru-
mental in ensuring that the discontinuation was successfully
completed in a manner that was both understandable and
acceptable to participants. This paper draws on the experiences
of only one of six research centres involved in this multicentre trial
and therefore the findings do not represent the diverse populations
of other settings. However, a number of concrete lessons for future
trials emerge from these analyses such as the benefits of ongoing
feedback mechanisms, devolved responsibility for local messaging,
gauging the accuracy with which messages are understood and
incorporating extended information about the role of IDMC’s.
These findings also support the recommendation in the Good
Participatory Practice guidelines that prior to trial implementation,
research teams need to develop plans for early termination of trials
in consultation with relevant stakeholders [27]. Researchers should
continue to document the process of early trial termination and
participant’s experiences of it, so as these examples can be used in
future trials to better prepare participants and community
structures for the potential of early trial termination [7].
More generally, these analyses highlight that enrolment in a
clinical trial is a dynamic experience for participants; they actively
engage in the trial, constantly learn new information, and
continuously re-evaluate the benefits of participation within the
context of their broader lives. This experience is also influenced by
changes in trial circumstances, such as premature discontinuation
of a study arm. Consequently changes to clinical trials have to take
account of this dynamic experience to ensure that the circum-
stances are still acceptable to participants and the community. The
Africa Centre sites experience of the discontinuation of the 2%
PRO2000/5 gel highlights the multiple benefits of incorporating
qualitative social science techniques in the trial protocol, not
merely to assess sexual behaviour, but to inform operational
procedures, messaging and to monitor and evaluate the dynamic
experience of participants.
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